WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 100374
CAS#: 13311-84-7
Description: Flutamide, also known as SCH13521, is a toluidine derivative and nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
MedKoo Cat#: 100374
Name: Flutamide
CAS#: 13311-84-7
Chemical Formula: C11H11F3N2O3
Exact Mass: 276.07218
Molecular Weight: 276.21
Elemental Analysis: C, 47.83; H, 4.01; F, 20.63; N, 10.14; O, 17.38
Flutamide, purity > 98%, is in stock. The same day shipping after order is received.
Synonym: SCH13521; SCH-13521; SCH 13521; Flucinom; Flugerel; Niftolid; Eulexin; Apimid; Chimax; Drogenil; Euflex; Eulexine; Flucinome; Fluken; Flulem; Flutabene; Flutacan; FlutaGry; Flutamex; Flutamin; Flutan; Flutaplex; Fugerel; Grisetin; Oncosal; Profamid; Prostacur; Prostadirex; Prostica; Prostogenat; Tafenil; Tecnoflut; Testotard. FLUT.
IUPAC/Chemical Name: N-(4-nitro-3-(trifluoromethyl)phenyl)isobutyramide
InChi Key: MKXKFYHWDHIYRV-UHFFFAOYSA-N
InChi Code: InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
SMILES Code: CC(C)C(NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1)=O
The following data is based on the product molecular weight 276.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
DRUG DESCRIPTION
EULEXIN Capsules contain flutamide, an acetanilid, nonsteroidal, orally active anti-androgen having the chemical name, 2-methyl-N-[4-nitro-3 (trifluoromethyl) phenyl] propanamide. Each capsule contains 125 mg flutamide. The compound is a buff to yellow powder with a molecular weight of 276.2. The inactive ingredients for EULEXIN Capsules include: corn starch, lactose, magnesium stearate, povidone, and sodium lauryl sulfate. Gelatin capsule shells may contain methylparaben, propylparaben, butylparaben, and the following dye systems: FD&C Blue 1, FD&C Yellow 6, and either FD&C Red 3 or FD&C Red 40 plus D&C Yellow 10, with titanium dioxide and other inactive ingredients.
Use in prostate cancer
Gonadotropin-releasing hormone (GnRH) is released by the hypothalamus in a pulsatile fashion; this causes the anterior pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates the testes to produce testosterone, which is metabolized to DHT by the enzyme 5α-reductase. DHT, and to a much smaller extent, testosterone, stimulate prostate cancer cells to grow. Therefore, blocking these androgens can provide powerful treatment for prostate cancer, especially metastatic disease. Normally administered are analogues of GnRH, such as leuprolide or goserelin. Although they stimulate the same receptors that GnRH does, since they are present continuously and not in a pulsatile manner, they serve to inhibit the pituitary and therefore block the whole chain. However, they initially cause a surge in activity; this is not solely a theoretical risk but may cause the cancer to flare. Flutamide was initially used at the beginning of GnRH-analogue therapy to block this surge, and it and other nonsteroidal anti-androgens continue in this use. There have been studies to investigate the benefit of adding an anti-androgen to surgical orchiectomy or its continued use with a GnRH analogue (combined androgen blockade, CAB). Adding anti-androgens to orchiectomy showed no benefit, while a small benefit was shown with adding anti-androgens to GnRH analogues
Unfortunately, therapies which lower testosterone levels, such as orchiectomy or GnRH-analogue administration, also have significant side effects. Compared to these therapies, treatment with antiandrogens exhibits "fewer hot flashes, less of an effect on libido, less muscle wasting, fewer personality changes, and less bone loss." However, antiandrogen therapy alone is less effective than surgery. Nevertheless, given the advanced age of many with prostate cancer, as well as other features, many men may choose antiandrogen therapy alone for a better quality of life. From: http://en.wikipedia.org/wiki/Flutamide.
